Mablink focuses its efforts on cancers with high unmet medical needs and, to demonstrate the high potential of its proprietary PSARlink™ technology, the first ADCs are addressing molecular targets for which they have already shown clinical promise.
Mablink is currently developing three ADC programs based on its proprietary linker, and exatecan (a topoisomerase I inhibitor) as the payload:
Discovery
Preclinical
Phase I
Phase II
Disc.
Precl.
Ph. I
Ph. II
MBK-103
Solid Tumors
Preclinical
MBK-102
Multiple Myeloma / Lymphomas
Preclinical
MBK-101
Acute Myeloid Leukemia
Preclinical